Sarepta Therapeutics Stock Forecast - Stock Analysis

5 days ago · The 21 analysts with 12-month price forecasts for SRPT stock have an average target of 179.38, with a low estimate of 75 and a high estimate of 230. The average target predicts an increase of 43.75% from the current stock price of 124.79.

75%
OFF

Sarepta Therapeutics Stock Forecast - Stock Analysis

2 weeks from now

stockanalysis.com

$175.72
OFF

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Analyst Ratings, Price ...

2 weeks from now

Sarepta Therapeutics Inc has a consensus price target of $175.72 based on the ratings of 25 analysts. The high is $230 issued by Leerink Partners on June 24, 2024.The low is $75 issued …

benzinga.com

$124.79
OFF

Sarepta Therapeutics (NASDAQ:SRPT) Stock Quotes, Forecast And …

2 weeks from now

5 days ago · The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $124.79 last updated January 10, 2025 at 4:00 PM EST. Q Does Sarepta Therapeutics (SRPT) pay a dividend?

benzinga.com

42%
OFF

Sarepta Therapeutics Stock Forecast - StockInvest.us

2 weeks from now

6 days ago · Buy or Hold candidate since Jan 06, 2025 Loss -2.42%. The Sarepta Therapeutics stock price fell by -1.17% on the last day (Friday, 10th Jan 2025) from $126.27 to …

stockinvest.us

36%
OFF

Sarepta Therapeutics (SRPT) Gets A Buy From Bank Of America …

2 weeks from now

Jan 7, 2025 · The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $182.06 average price target, a 42.36% upside from current …

businessinsider.com

$1.72
OFF

Sarepta Therapeutics Stock Supported By LGMD Pipeline Progress, …

2 weeks from now

2 days ago · Sarepta Therapeutics stock supported by LGMD pipeline progress, says Piper Sandler ... surpassing Piper Sandler's forecast of $1.72 billion and the consensus estimate of …

investing.com

$200.00
OFF

Sarepta Therapeutics (NASDAQ:SRPT) Earns "Buy" Rating From

2 weeks from now

2 days ago · Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a report on Thursday, November …

marketbeat.com

31%
OFF

SRPT - Sarepta Therapeutics Inc Stock Price Forecast 2025

2 weeks from now

The Sarepta Therapeutics Inc (SRPT) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $130.48, representing a +3.31% increase from …

stockscan.io

$187.75
OFF

Sarepta Therapeutics Stock Forecast, Price, News, Analysis (SRPT ...

2 weeks from now

Aug 7, 2024 · 🚀 Sarepta Therapeutics stock price forecast: $187.75; Market Cap: 14.37B, Enterprise value: 11.93B, P/E: -16.72, PEG ratio: 0.24, EPS: 0.13, Revenue: 1.40B, EBITDA ...

strike.market

FAQs about Sarepta Therapeutics Stock Forecast - Stock Analysis Coupon?

Is Sarepta Therapeutics Inc (SRPT) stock a good investment?

According to our live Forecast System, Sarepta Therapeutics Inc stock is a not so good long-term (1-year) investment*. "SRPT" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "SRPT" projections. ...

How do analysts evaluate Sarepta Therapeutics?

Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sarepta Therapeutics compared to the broader market. Price Targets: Understanding forecasts, analysts offer estimates for Sarepta Therapeutics's future value. ...

What happened to Sarepta Therapeutics stock?

The Sarepta Therapeutics stock price fell by -1.56% on the last day (Thursday, 8th Jun 2023) from $127.90 to $125.91. During the last trading day the stock fluctuated 2.61% from a day low at $125.79 to a day high of $129.08. The price has fallen in 6 of the last 10 days and is down by -4.15% for this period. ...

Is Sarepta Therapeutics a good buy?

Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ascendis Pharma, and PTC Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $182.06 average price target, a 42.36% upside from current levels. ...

Does Sarepta Therapeutics stock have a sell signal?

The Sarepta Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. ...

Does Sarepta Therapeutics have a high debt-to-equity ratio?

Debt Management: With a high debt-to-equity ratio of 1.63, Sarepta Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain. Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. ...